Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi Re-rates REMEGEN (09995.HK) at Buy/ High Risk w/ TP $105
Recommend 2 Positive 4 Negative 3 |
||||
|
||||
|
Citi Research issued a research report renewing rating at Buy/High Risk on REMEGEN (09995.HK) after a period of Rating Suspended, with a target price of $105, as the Group's collaboration with AbbVie on the PD-1/VEGF candidate RC148, which further expanded the global potential of its pipeline candidates. The broker believed that, following the completion of the collaboration, market focus should shift to the future global Phase III clinical studies and commercialization potential based on clinical data and competitive landscape. Regarding the global development of telitacicept, the top-line data from its Phase III clinical study for treating myasthenia gravis may be announced in 1H27, while the Phase III clinical trial for sicca syndrome will commence in 1H26. The domestic sales trend of telitacicept was positive, and the Company's management aims to achieve breakeven in 2026. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
